FDA Orders St. Jude To Expand Surveillance Of ICD Leads, Including Durata
This article was originally published in The Gray Sheet
Executive Summary
The agency announced Section 522 post-market surveillance orders that target St. Jude Medical’s recalled Riata leads, as well as the currently marketed Durata leads.
You may also be interested in...
St. Jude Durata ICD Lead Insulation Breaches Probed In Hauser Study
MAUDE analysis suggests some trouble spots for St. Jude’s newer Optim-insulated ICD leads, according to researchers. But the company says the overall data shows the products to be as safe and reliable as competitors’ offerings.
St. Jude Stops Selling CRT Leads Showing Riata-Like Insulation Abrasion
The action does not impact QuickFlex µ bipolar and Quartet quadripolar leads, which employ the firm’s proprietary Optim insulation coating, but it could add to St. Jude's perception problems, analysts suggest.
St. Jude Tries To Get Ahead Of Questions On Durata ICD Leads
The company hopes an independent analysis of its Optim-insulated Durata leads will address questions from the clinical community based on concerns with its earlier-generation Riata devices.